ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report - Summary - MDSpire
Advertisement
ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report
To illustrate the feasibility of incorporating ctDNA monitoring into treatment decisions for HER2-positive breast cancer with brain metastases, based on a case report.
Key Findings:
ctDNA monitoring detected disease activity approximately three months prior to radiologic evidence of brain metastases, based on a single case report.
Genomic profiling revealed alterations including MET amplification and HER2 V777L mutation.
Treatment with trastuzumab deruxtecan and pyrotinib resulted in intracranial disease control over 17 months, as observed in this case.
Interpretation:
The findings indicate earlier detection of disease activity through ctDNA monitoring, but clinical outcomes require further validation.
Limitations:
The study is based on a single case report, limiting generalizability.
The impact of earlier intervention on clinical outcomes remains unestablished, as this is a case report.
Conclusion:
The case supports the evaluation of ctDNA-guided treatment approaches in HER2-positive breast cancer, as suggested by the findings.
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
